The leukotriene antagonist montelukast as a therapeutic agent for atopic dermatitis

Yanase, David J.; David-Bajar, Kathleen M.

doi:10.1067/mjd.2001.111352

Cited by 77 publications

(41 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a pilot study applying zileuton, a 5-LO inhibitor, to six patients with severe AD, all individuals showed significant improvement of disease (57). Other small studies testing the effect of CysLT 1 R inhibitors showed mixed results (58)(59)(60). Notably, the latest results from mouse models summarized in this Viewpoint article do not provide a rationale for using CysLT 1 R inhibitors in AD patients, but rather CysLT 2 R inhibitors.…”

Section: Discussionmentioning

confidence: 99%

Leukotrienes orchestrating allergic skin inflammation

Sadik

Sezin

Kim

2013

Experimental Dermatology

View full text Add to dashboard Cite

Leukotrienes constitute a group of lipid mediators, which may be subdivided into two groups, with leukotriene B 4 on the one hand and cysteinyl leukotrienes on the other. Although leukotrienes are abundantly expressed in skin affected by diverse chronic inflammatory diseases, including atopic dermatitis, psoriasis, pemphigus vulgaris and bullous pemphigoid, their pathological roles in these diseases have remained elusive. Recent data now reveal that both leukotriene B 4 and cysteinyl leukotrienes are indispensable in the pathogenesis of atopic dermatitis, with leukotriene B 4 initiating the recruitment of inflammatory cells, particularly neutrophils and T H 2 cells into the skin, and cysteinyl leukotrienes later inducing characteristic structural alterations of chronically affected skin, specifically skin fibrosis and keratinocyte proliferation. Thus, these results reveal a sequential cooperation of LTB 4 and cysteinyl leukotrienes to initiate and perpetuate allergic skin inflammation. These new insights highlight leukotrienes as promising therapeutic targets in allergic skin inflammation and should encourage more research into the role of leukotrienes in other inflammatory skin diseases.

show abstract

Section: Discussionmentioning

confidence: 99%

Leukotrienes orchestrating allergic skin inflammation

Sadik

Sezin

Kim

2013

Experimental Dermatology

View full text Add to dashboard Cite

show abstract

“…Epicutaneous application of LTB 4 results in a cutaneous in¯ammatory response [26], and animal experiments showed that LTB 4 might be involved in the mechanisms leading to pain and pruritus [1,2,10]. Both zileuton (which inhibits the synthesis of LTB 4 and the cysteinyl LTs), as well as dierent cysteinyl LT receptor antagonists (which block the receptor binding of the cysteinyl LTs but not LTB 4 ) are reported to have bene®cial eects on the pruritus in patients with atopic dermatitis, which is an in¯ammatory skin disorder accompanied by extreme pruritus [3,35,36]. The latter ®ndings and the favourable eects of zileuton in SLS indicate that LTB 4 may play an important role in the pathogenesis of pruritus.…”

Section: Discussionmentioning

confidence: 98%

Clinical and biochemical effects of zileuton in patients with the Sjögren-Larsson syndrome

et al. 2001

View full text Add to dashboard Cite

show abstract

“…Yanase et al verglichen in einer doppelblinden placebokontrollierten Studie bei 8 erwachsenen Patienten die Wirksamkeit von Montelukast mit der eines Placebopräparates [69]. Unter Montelukast war eine signifikante Besserung des Hautzustandes zu beobachten.…”

Section: Leukotrienantagonistenunclassified

Symptomatische Therapie der atopischen Dermatitis

et al. 2003

View full text Add to dashboard Cite

The optimal treatment of atopic dermatitis requires regular medical supervision. The course of this chronic skin disease is influenced by multiple triggers which are relevant for the treatment. The mainstays of topical therapy include regular use of emollients coupled with antimicrobial substances, corticosteroids and immune modulators as required. Ultraviolet radiation and immunosuppressive regimens represent further options for the treatment of severe exacerbations and may lead to long term improvement. Data from experimental studies provide insight into possible future treatment methods.

show abstract

The leukotriene antagonist montelukast as a therapeutic agent for atopic dermatitis

Cited by 77 publications

References 16 publications

Leukotrienes orchestrating allergic skin inflammation

Leukotrienes orchestrating allergic skin inflammation

Clinical and biochemical effects of zileuton in patients with the Sjögren-Larsson syndrome

Symptomatische Therapie der atopischen Dermatitis

Contact Info

Product

Resources

About